Efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke

LI Long; WANG Bin; QU Zheng; HUANG Junrong

doi:10.6039/j.issn.1001-0408.2023.08.16

您当前的位置：

首页 >

文章列表页 >

Efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke

更新时间：2023-04-25

- Efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke
- ZHONGGUO YAOFANG Vol. 34, Issue 8, Pages: 978-982(2023)
- 作者机构：
  
  1.牡丹江医学院附属第二医院药剂科，黑龙江牡丹江　157011
  2.牡丹江医学院药学院，黑龙江牡丹江　157011
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.08.16
  CLC： R956;R544.1
- Published：30 April 2023，
  
  Received：31 July 2022，
  
  Revised：14 March 2023，
扫描看全文
李龙,王彬,曲政等.依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的疗效、安全性和经济性 ^Δ[J].中国药房,2023,34(08):978-982.

LI Long,WANG Bin,QU Zheng,et al.Efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke[J].ZHONGGUO YAOFANG,2023,34(08):978-982.
李龙,王彬,曲政等.依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的疗效、安全性和经济性 ^Δ[J].中国药房,2023,34(08):978-982. DOI： 10.6039/j.issn.1001-0408.2023.08.16.

LI Long,WANG Bin,QU Zheng,et al.Efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke[J].ZHONGGUO YAOFANG,2023,34(08):978-982. DOI： 10.6039/j.issn.1001-0408.2023.08.16.

摘要

目的

评价依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的疗效、安全性和经济性，为临床治疗选择提供决策参考。

方法

收集2021年1月－2021年12月住院治疗的488例急性缺血性脑卒中患者的病历资料，根据治疗方案分为两组，其中依达拉奉右莰醇组268例，复方脑肽节苷脂组220例。应用倾向性评分匹配法平衡两组基线水平后，依据治疗前后美国国立卫生研究院卒中量表（NIHSS）评分的变化情况评定疗效；从医院不良反应上报系统中收集患者的不良反应发生情况；从中国卫生体系角度出发，分析两种方案的经济性，并进行单因素敏感性分析。

结果

倾向性评分匹配后，依达拉奉右莰醇组和复方脑肽节苷脂组各纳入患者125例，有效率分别为81.6%和74.4%，疗效无显著性差异，成本平均值分别为13 560.30元和14 958.68元，依达拉奉右莰醇组的成本更低。两组均未检索到不良反应上报信息。单因素敏感性分析结果显示，复方脑肽节苷脂组的其他药品费为较为敏感的参数。

结论

依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的短期疗效和安全性相当，但依达拉奉右莰醇方案的成本更低，是更为经济的方案。

Abstract

OBJECTIVE

To evaluate efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke， and to provide decision-making reference for clinical treatment selection.

METHODS

The medical records of 488 patients with acute ischemic stroke hospitalized from Jan. 2021 to Dec. 2021 were collected and divided into two groups according to the treatment plan， i.e. 268 patients in edaravone dexborneol group， and 220 patients in compound porcine cerebroside ganglioside group. After baseline levels of the two groups were balanced using propensity score matching method， curative effect was evaluated according to the changes of NIHSS scores before and after treatment； the occurrence of adverse drug reactions in patients were collected from the hospital adverse reaction reporting system； from the perspective of China’s health system， the cost-effectiveness of the two options were analyzed， and one-way sensitivity analysis was conducted.

RESULTS

After the propensity score matching， 125 patients were included in the edaravone dexborneol group and compound porcine cerebroside ganglioside group， respectively. The response rates were 81.6% and 74.4%， respectively， with no significant difference. The average costs were 13 560.30 yuan and 14 958.68 yuan， respectively； the cost of edaravone dexborneol group was lower than that of compound porcine cerebroside ganglioside group. No adverse reaction reporting information was retrieved in both groups. Results of one-way sensitivity analysis showed that other drug costs in compound porcine cerebroside ganglioside group was relatively sensitive parameters.

CONCLUSIONS

Short-term efficacy and safety of edaravone dexborneol are equivalent to those of compound porcine cerebroside ganglioside in treating acute ischemic stroke. But edaravone dexborneol regimen had lower cost and is a more economical scheme.

关键词

依达拉奉右莰醇复方脑肽节苷脂神经保护剂缺血性脑卒中有效性安全性经济性最小成本分析

Keywords

compound porcine cerebroside gangliosideneuroprotective agentischemic strokeefficacysafetycost-effectivenesscost-minimization analysis

references

URIAKOSE D，XIAO Z C. Pathophysiology and treatment of stroke：present status and future perspectives[J]. Int J Mol Sci，2020，21（20）：7609.

郭昭廷，周黎，项予良，等. 基于真实世界数据的银杏内酯注射液治疗脑卒中的疗效及药物经济学评价[J]. 中国药物经济学，2021，16（1）：35-42.

张瑛，陆征宇，赵虹. 神经保护疗法在卒中后应用的研究进展[J]. 神经损伤与功能重建，2021，16（5）：266-269.

《中国脑卒中防治报告2019》编写组.《中国脑卒中防治报告2019》概要[J]. 中国脑血管病杂志，2020，17（5）：272-281.

中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志，2018，51（9）：666-682.

杨晓洁. 依达拉奉右莰醇联合阿替普酶静脉溶栓对急性脑梗死患者出血性转化及神经功能的影响[J]. 现代诊断与治疗，2022，33（8）：1153-1156.

XU J，WANG A X，MENG X，et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke：a phase Ⅲ，randomized，double-blind，comparative trial[J]. Stroke，2021，52（3）：772-780.

李兴明，刘娟娟，陈俊斌，等. 复方脑肽节苷脂注射液对急性脑梗死的临床疗效及对患者Lp-PLA2 hs-CRP NSE水平的影响[J]. 河北医学，2020，26（3）：393-397.

刘莹，于生元，顾平，等. 复方脑肽节苷脂注射液治疗急性缺血性脑卒中388例回顾性研究[J]. 中国合理用药探索，2021，18（8）：61-66.

王慧媛，杨莉，赵志刚. 2012－2016年我国六城市神经保护剂用药现状调查[J]. 中国医药导报，2018，15（3）：46-51.

王慧媛. 我国六城市神经保护剂用药调查与合理性评价[J]. 实用药物与临床，2018，21（5）：586-593.

潘向滢，汪利萍，张月清，等. 脑卒中评价量表的研究进展[J/OL]. 中华危重症医学杂志（电子版），2016，9（3）：205-207（2016-06-01）[2022-06-12]. https：//d.wanfangdata.com.cn/periodical/zhwzzyxzz201603014https://d.wanfangdata.com.cn/periodical/zhwzzyxzz201603014. DOI：10.3877/cma.j.issn.1674-6880.2016.03.014http://dx.doi.org/10.3877/cma.j.issn.1674-6880.2016.03.014.

伊恋，李星达，王建秀，等. 依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床观察[J]. 中国药房，2016，27（29）：4130-4132.

刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国市场出版社，2020：10-11.

崔鑫，韩晟，刘峘，等.基于决策树模型的芪龙胶囊治疗缺血性脑卒中的成本-效果分析[J].中国药物经济学，2022，17（11）：5-9，15.

黄冰琳.万古霉素治疗药物监测的临床应用分析和经济学评价[D]. 福州：福建医科大学，2020.

律颖. 急性缺血性脑卒中的药物治疗[J]. 人民军医，2000，19（1）：305-306.

贺旭，王伟，汤艳，等. 神经保护剂在脑缺血后大脑神经再生中的作用[J]. 中国老年学杂志，2020，40（17）：3787-3790.

吴飞华，余辉，王叶遵. 基层医院药品不良反应漏报情况调查与原因分析[J]. 临床合理用药杂志，2021，14（2）：147-149.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Semaglutide in the treatment of type 2 diabetes mellitus： rapid health technology assessment

Efficacy and safety comparison of lacosamide and carbamazepine in the treatment of adult patients with newly diagnosed epilepsy

Meta-analysis of efficacy and safety of cabozantinib in the treatment of advanced thyroid cancer

Real-world research of vonoprazan and amoxicillin dual therapy for Helicobacter pylori eradication

Network meta-analysis of the effectiveness and safety of 3 kinds of snake venom hemocoagulase drugs for hemostasis in abdominal surgery

Related Author

WANG Sihua

WANG Sheng

WANG Yan

LUAN Jiajie

GUO Xiaqing

LI Guofei

SUN Yuhua

ZHENG Donglin

Related Institution

Dept. of Pharmacy， Wannan Medical College

Dept. of Pharmacy， Yijishan Hospital of Wannan Medical College

First Ward， Dept. of Neurology， Huaihe Hospital of Henan University

Dept. of Oncology， Lanzhou University Second Hospital

Dept. of Geriatrics， Lanzhou University Second Hospital

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰